Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, School of Pharmacology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
Curr Vasc Pharmacol. 2024;22(2):95-105. doi: 10.2174/0115701611258090231221082502.
The ribonucleic acid (RNA)-binding protein Cytoplasmic Polyadenylation Element Binding Protein 1 (CPEB1), a key member of the CPEB family, is essential in controlling gene expression involved in both healthy physiological and pathological processes. CPEB1 can bind to the 3'- untranslated regions (UTR) of substrate messenger ribonucleic acid (mRNA) and regulate its translation. There is increasing evidence that CPEB1 is closely related to the pathological basis of atherosclerosis. According to recent investigations, many pathological processes, including inflammation, lipid metabolism, endothelial dysfunction, angiogenesis, oxidative stress, cellular senescence, apoptosis, and insulin resistance, are regulated by CPEB1. This review considers the prevention and treatment of atherosclerotic heart disease in relation to the evolution of the physiological function of CPEB1, recent research breakthroughs, and the potential participation of CPEB1 in atherosclerosis.
核糖核酸(RNA)结合蛋白细胞质多聚腺苷酸化元件结合蛋白 1(CPEB1)是 CPEB 家族的关键成员,在控制涉及健康生理和病理过程的基因表达中至关重要。CPEB1 可以与底物信使核糖核酸(mRNA)的 3'非翻译区(UTR)结合,并调节其翻译。越来越多的证据表明 CPEB1 与动脉粥样硬化的病理基础密切相关。根据最近的研究,许多病理过程,包括炎症、脂质代谢、内皮功能障碍、血管生成、氧化应激、细胞衰老、细胞凋亡和胰岛素抵抗,都受到 CPEB1 的调节。本综述考虑了与 CPEB1 生理功能的演变、最近的研究突破以及 CPEB1 在动脉粥样硬化中的潜在参与相关的动脉粥样硬化性心脏病的预防和治疗。